ArticleAging cell2025
Epigenetic Clock Analysis of Sex Chromosome Aneuploidies.
Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sex differences in lifespan are pervasive in nature and in humans, yet the contribution of sex chromosomes to DNA methylation-linked aging remains incompletely defined. We leveraged human sex chromosome aneuploidies to test whether X and Y chromosome dosage influences epigenetic aging, quantified with DNA methylation (DNAm) clocks. In whole blood from individuals with karyotypes 46,XX (female) and 46,XY, 47,XXY, 47,XYY (male), we measured epigenetic age and age acceleration using a first-generation clock (Skin & Blood) and two next-generation clocks (GrimAge and DunedinPACE), and examined the components underlying GrimAge. Next-generation clocks indicated lower epigenetic age acceleration and a slower pace of aging in 47,XXY versus 46,XY. In GrimAge, a weighted sum of DNAm surrogates, higher DNAmLeptin (negatively weighted) and lower DNAmPACKYRS (positively weighted smoking proxy) in 47,XXY jointly reduced GrimAge in comparison to 46,XY. DunedinPACE also indicated a slower pace of aging in 47,XXY. In contrast, the first-generation Skin & Blood clock indicated higher age acceleration in 47,XXY and 47,XYY than in 46,XY. Enrichment analyses of autosomal EWAS loci highlighted immune pathways and karyotype-specific signatures, for example, metabolic/cancer-related processes in 47,XXY and renal/amino acid transport processes in 47,XYY. Overall, X chromosome gain in 47,XXY was associated with lower GrimAge and slower DunedinPACE, whereas the Skin & Blood clock diverged, suggesting that DNAm clocks capture partially distinct biological domains of aging differentially perturbed by sex-chromosome dosage. These findings motivate larger, age-spanning studies with direct phenotyping to define mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.